{"id":"open-label-rifaximin","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL1617","moleculeType":"Small molecule","molecularWeight":"785.89"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Rifaximin is a rifamycin antibiotic that targets bacterial RNA polymerase, leading to a decrease in bacterial RNA synthesis and ultimately reducing the bacterial load in the gut. This mechanism of action is particularly effective against Gram-negative bacteria, which are often implicated in conditions such as hepatic encephalopathy.","oneSentence":"Rifaximin works by inhibiting bacterial RNA synthesis, thereby reducing bacterial load in the gut.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:24:25.860Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatic encephalopathy"},{"name":"Irritable bowel syndrome with diarrhea (IBS-D)"}]},"trialDetails":[{"nctId":"NCT07285785","phase":"PHASE4","title":"Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea","status":"RECRUITING","sponsor":"Bausch Health Americas, Inc.","startDate":"2026-02-11","conditions":"Diarrhea, Gastroenteritis, Bacterial Infection","enrollment":54},{"nctId":"NCT05159427","phase":"PHASE1","title":"Pharmacokinetic Study of Single-Dose Modified Release Glipizide in Healthy Volunteers","status":"RECRUITING","sponsor":"University of Michigan","startDate":"2022-03-15","conditions":"Human Gastrointestinal Physiology Data","enrollment":40},{"nctId":"NCT07381257","phase":"EARLY_PHASE1","title":"Efficacy and Safety of Rifaximin-α in Treating MASLD","status":"RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2026-01-15","conditions":"Metabolic Dysfunction-Associated Steatotic Liver Disease","enrollment":60},{"nctId":"NCT06443502","phase":"PHASE3","title":"A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-11-19","conditions":"Pouchitis","enrollment":30},{"nctId":"NCT06483737","phase":"NA","title":"Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE)","status":"RECRUITING","sponsor":"General Hospital of Shenyang Military Region","startDate":"2025-06-24","conditions":"Overt Hepatic Encephalopathy","enrollment":174},{"nctId":"NCT06743464","phase":"NA","title":"Effect of Perioperative Oral Rifaximin on Early Graft Dysfunction in Adult Living Donor Liver Transplant","status":"RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2024-12-01","conditions":"Chronic Liver Disease","enrollment":100},{"nctId":"NCT06328088","phase":"","title":"Vegetarian Versus Non Vegetarian Based Diet in the Recurrence of Hepatic Encephalopathy in Patients With Cirrhosis: An Open Label Pilot Study","status":"RECRUITING","sponsor":"Sir Ganga Ram Hospital","startDate":"2024-02-16","conditions":"Hepatic Encephalopathy","enrollment":40},{"nctId":"NCT03818672","phase":"PHASE4","title":"Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects","status":"TERMINATED","sponsor":"Bausch Health Americas, Inc.","startDate":"2019-01-29","conditions":"Severe Hepatic Impairment","enrollment":5},{"nctId":"NCT03856359","phase":"PHASE2","title":"Trial of Rifaximin in Probable Alzheimer's Disease","status":"COMPLETED","sponsor":"Duke University","startDate":"2019-04-09","conditions":"Alzheimer's Disease","enrollment":10},{"nctId":"NCT03712280","phase":"PHASE2","title":"MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy)","status":"COMPLETED","sponsor":"Mallinckrodt","startDate":"2018-12-01","conditions":"Hepatic Cirrhosis, Hepatic Encephalopathy (HE)","enrollment":50},{"nctId":"NCT04043897","phase":"PHASE2","title":"Efficacy and Safety of Oral Rifaximin in Patients With Active Microscopic Colitis","status":"RECRUITING","sponsor":"Eugene F Yen, MD","startDate":"2018-06-29","conditions":"Microscopic Colitis","enrollment":10},{"nctId":"NCT00743912","phase":"PHASE1","title":"Open-Label Study to Evaluate the Effect of Rifaximin on Midazolam in Normal Healthy Volunteers","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2008-09","conditions":"Pharmacokinetic","enrollment":24},{"nctId":"NCT01842581","phase":"PHASE4","title":"The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2013-01-08","conditions":"Hepatic Encephalopathy, Cirrhosis","enrollment":222},{"nctId":"NCT00686920","phase":"PHASE3","title":"Safety and Tolerability Study of Rifaximin in Participants With a History of Hepatic Encephalopathy","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2007-03-07","conditions":"Hepatic Encephalopathy","enrollment":322},{"nctId":"NCT03415698","phase":"PHASE2, PHASE3","title":"G-CSF in Decompensated Cirrhosis: an Open Label Trial","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2016-07","conditions":"Cirrhosis, Liver","enrollment":100},{"nctId":"NCT01543178","phase":"PHASE3","title":"Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2012-02","conditions":"Irritable Bowel Syndrome With Diarrhea","enrollment":2583},{"nctId":"NCT02011841","phase":"PHASE3","title":"Rifaximin for the Secondary Prevention of Spontaneous Bacterial Peritonitis Recurrence in Cirrhotic Patients","status":"WITHDRAWN","sponsor":"Seoul National University Hospital","startDate":"2014-01","conditions":"Spontaneous Bacterial Peritonitis","enrollment":""},{"nctId":"NCT01662791","phase":"PHASE3","title":"Weight Loss in Parkinson's Disease and Role of Small Bowel Bacterial Overgrowth","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2012-09","conditions":"Parkinson's Disease","enrollment":49},{"nctId":"NCT01946906","phase":"PHASE4","title":"The Rifaximin Study in CVID","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2013-10","conditions":"Common Variable Immunodeficiency (CVID)","enrollment":40},{"nctId":"NCT01069133","phase":"PHASE1, PHASE2","title":"Study of Rifaximin in Minimal Hepatic Encephalopathy","status":"COMPLETED","sponsor":"Hunter Holmes Mcguire Veteran Affairs Medical Center","startDate":"2010-02","conditions":"Minimal Hepatic Encephalopathy","enrollment":20},{"nctId":"NCT00577772","phase":"NA","title":"Transit Time and Bacterial Overgrowth Using SmartPill Capsule","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2007-11","conditions":"Small Bowel Bacterial Overgrowth, Gastrointestinal Diseases, Stomach Diseases","enrollment":17}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["rifaximin"],"phase":"phase_3","status":"active","brandName":"open-label rifaximin","genericName":"open-label rifaximin","companyName":"Bausch Health Americas, Inc.","companyId":"bausch-health-americas-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rifaximin works by inhibiting bacterial RNA synthesis, thereby reducing bacterial load in the gut. Used for Hepatic encephalopathy, Irritable bowel syndrome with diarrhea (IBS-D).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}